Key result
Intravenous procainamide depressed retrograde AV nodal conduction, abolishing ventriculoatrial conduction in 5 of 13 patients and prolonging the cycle length for block in 7 of 13.
Why the study?
Does intravenous procainamide depress retrograde AV nodal conduction in patients without AV nodal reentrant tachycardia or accessory pathways?
Does intravenous procainamide depress retrograde AV nodal conduction in patients without AV nodal reentrant tachycardia or accessory pathways?
Intravenous procainamide almost uniformly depresses retrograde AV nodal conduction in the intact human heart, indicating this response does not necessarily imply the presence of AV nodal bypass tracts.
No takes yet. Share an insight, caveat, or question.
Procainamide depresses retrograde AV nodal conduction without bypass tracts; supports reevaluation of EP criteria but leaves clinical implications open.
Shenasa et al. (1982) studied Without AV nodal reentrant tachycardia (n=13). Procainamide vs. Control (before procainamide) was evaluated on Ventriculoatrial (VA) conduction. Intravenous procainamide depressed retrograde AV nodal conduction, abolishing ventriculoatrial conduction in 5 of 13 patients and prolonging the cycle length for block in 7 of 13.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: